Hypothesis

Age‑associated accumulation of mitochondrial DNA (mtDNA) lesions in endothelial cells triggers a systemic pro‑thrombotic state by packaging damaged mtDNA into extracellular vesicles (EVs) that activate the cytosolic DNA sensor cGAS‑STING pathway in circulating monocytes and platelets, leading to tissue factor (TF) expression and elevated Factor VIII/VWF levels.

Mechanistic Model

1. mtDNA damage – With age, polymerase γ errors and deficient mitophagy increase heteroplasmic mtDNA deletions and point mutations, raising mitochondrial ROS and releasing oxidized mtDNA fragments into the cytosol 2.
2. EV loading – Stressed endothelial cells sort oxidized mtDNA into shedding microvesicles and exosomes via ESCRT‑dependent pathways, a process amplified by disrupted mitochondrial‑ER calcium signaling.
3. EV‑mediated cGAS‑STING activation – Circulating EVs deliver mtDNA to monocytes and platelets, where cytosolic cGAS senses the DNA, synthesizes 2′‑3′‑cGAMP, and drives STING‑dependent IRF3/NF‑κB signaling.
4. Inflammatory‑thrombotic output – STING signaling upregulates NF‑κB‑dependent TF, IL‑6, and P‑selectin, while IRF3 promotes type‑I interferon that further stimulates endothelial VWF release.
5. Systemic effect – EV‑borne signaling creates a feed‑forward loop: endothelial activation releases more EVs, sustaining elevated plasma TF activity, FVIII, and VWF, which together raise thrombotic risk 4.

Testable Predictions

• Prediction 1: Plasma EV‑associated mtDNA copy number and oxidation level will correlate positively with plasma TF activity, FVIII, and VWF in humans across age strata.
• Prediction 2: Endothelial‑specific knockout of the mtDNA repair gene OGG1 in mice will increase EV‑mtDNA load, elevate STING activation in monocytes, and cause a pro‑thrombotic phenotype (shortened tail‑bleeding time, increased fibrin deposition) without altering nuclear DNA damage markers.
• Prediction 3: Pharmacological inhibition of STING (e.g., C‑176) or neutralization of circulating EVs (using annexin V‑coated beads) will normalize TF/FVIII/VWF levels in aged mice despite persistent mtDNA mutations.

Potential Experiments

• Isolate plasma EVs from young (3 mo) and old (24 mo) mice; quantify mtDNA by qPCR (ND1) and oxidative damage (8‑oxoguanine ELISA). Correlate with ELISA‑measured TF, FVIII, VWF.
• Generate Tie2‑Cre; Ogg1^fl/fl mice; assess EV mtDNA, monocyte p‑STING (flow cytometry), and tail‑bleeding assay.
• Treat aged mice with STING inhibitor C‑176 for 4 weeks; measure coagulation parameters and EV mtDNA.
• In vitro, expose human monocytes to endothelial EVs from mtDNA‑mutated cybrids; block cGAS with RU.521 to see if TF expression drops.

If these predictions hold, the data would support the concept that the mitochondrial genome, not the nuclear genome, drives the age‑related hemostatic shift, redirecting longevity strategies toward preserving mtDNA integrity and blocking EV‑mediated innate immune activation.